A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR) 20 mg in the Prevention of Cardiovascular Events Among Subjects With Low Levels of Low Density Lipoprotein(LDL) Cholesterol & Elevated Levels of C-Reactive Protein

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR) 20 mg in the Prevention of Cardiovascular Events Among Subjects With Low Levels of Low Density Lipoprotein(LDL) Cholesterol & Elevated Levels of C-Reactive Protein

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Cardiovascular disorders; Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms JUPITER
  • Sponsors AstraZeneca
  • Most Recent Events

    • 30 Aug 2017 Results comparing methods of generalizing RCT results to target populations without individual level data, presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management
    • 27 Apr 2017 Results (n=314) of nested case control analysis assessing correlation between HDL biomarkers and incidence of cardiovascular events published in the Circulation
    • 01 Jul 2016 Results assessing relation of ALT levels to cardiovascular events and statin efficacy (n = 17,515) published in the American Journal of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top